key: cord-0868590-6x8s0j29 authors: Jung, Jaehun title: Preparing for the Coronavirus Disease (COVID-19) Vaccination: Evidence, Plans, and Implications date: 2021-02-09 journal: J Korean Med Sci DOI: 10.3346/jkms.2021.36.e59 sha: 2408b55a82c33fcecf8eb6c15e0b2b56f383102f doc_id: 868590 cord_uid: 6x8s0j29 The formation of herd immunity through vaccination is a key point in overcoming the coronavirus disease 2019 (COVID-19) pandemic. To acquire herd immunity, a high vaccination rate is required, which is necessary to instill confidence in the public regarding the effectiveness and safety of the vaccine. In the real-world setting, thorough preparation of components, such as priority setting, vaccine delivery, logistics, and side-effect monitoring is necessary to overcome vaccine hesitancy. Each country prioritizes vaccination since healthcare workers, nursing facility residents, and the elderly population, and similar trends are found between countries. Vaccination is performed at large centers and medical institutions operated by the country, and variations are dependent on the environment of each country. The transport of mRNA vaccines is a challenging task, and to this end, each government is striving for safe distribution. In addition, each authority operates a surveillance system to monitor the safety of vaccines, and Korea needs to produce evidence for monitoring effects and side effects with expertise. Even after the acquisition of herd immunity, COVID-19 is highly likely to remain an endemic infectious disease, and a higher immunity level may be required because of variants of the virus. If the spread of variants of concern continues, a booster vaccination may be required. Therefore, non-pharmaceutical interventions, such as social distancing, wearing a mask, and epidemiological investigation should be maintained. Coronavirus disease 2019 (COVID-19) has caused worldwide damage and is still prevalent as of February 2021. The third wave, which started in November 2020, is affecting most countries, including the United States, the United Kingdom, and Europe. 1 In response to the pandemic, countries around the world have applied non-pharmaceutical interventions, such as quarantine, diagnostic testing, contact tracing, social distancing, and wearing masks. 2 Some countries have successfully blocked outbreaks, but most countries have just delayed the outbreak. When most pandemic infectious diseases spread in the community, the outbreak continues until herd immunity is established and several waves of the outbreak have occurred. 3 Unlike the pandemic of the past, humans have succeeded in developing vaccines for multiple platforms based on advanced biotechnology, and vaccinations began in the US in December 2020. On January 28, 2021, the Republic of Korea also announced a plan to initiate COVID-19 vaccination. To achieve the national goal of herd immunity, it is important to review the cases of the countries, which have already started vaccination, and to establish a thorough plan by collecting sound scientific evidence. This article summarizes Korea's vaccination plan and reviews preparations in major countries. In particular, examples and evidence of vaccination priority, logistics, storage, and side effect monitoring, and provide a scientific basis for possible problems after vaccination are presented in this article. In addition, topics of social change after vaccination have been discussed. The initial phase of vaccination will start in February 2021. The priority target is 60,000 health-care workers who are directly related to COVID-19. In addition, vaccinations are provided for the elderly in nursing homes and long-term care facilities, as well as for inpatients and workers in mental rehabilitation hospitals. Vaccinations will begin in March for the first responders, such as workers at high-risk medical institutions and epidemiological investigators. Vaccinations for high-risk groups will start in May. High-risk groups include individuals who are 65 years of age or older, disabled, and healthcare professionals. The rest of the population will be vaccinated from July onwards. 4 The government of the Republic of Korea had specified the time of formation of herd immunity in November 2021 and proposed the goal of completing vaccinations for 70% of the population. Therefore, 70% of the population must complete the first vaccination by at least the end of October 2021. This is because the second dose of vaccination is given an average of 1 month after the first dose, and the complete protection effect is exerted only after the second dose. In Korea, vaccination centers will be installed for each region, starting with at least four centers, and the number of centers will increase sequentially to 250 by the second half of 2020. These vaccination centers will handle mRNA vaccines that require cryogenic storage. Other types of vaccines will be implemented at 10,000 pre-designated private medical institutions where existing systems, such as influenza vaccines, are generally maintained (Fig. 1) . The vaccines that have been confirmed to be introduced in Korea are viral vector vaccines (manufacturer: AstraZeneca, JNJ), mRNA vaccines (manufacturer: Pfizer/bioNTech, Moderna) , and a protein subunit vaccine (manufacturer: NovaVax) is under contract. The mRNA vaccine has been reported to have an efficacy of 95% 5, 6 and is currently being used in several countries. The efficacy of the viral vector vaccine has been reported to be lower than that of the mRNA vaccine, but it also meets the minimum efficacy criteria of the World Health Organization and has the advantage of being easy to store and inoculate. The viral vector vaccine and protein sub-unit vaccine, for which the results of a new interim phase 3 clinical trial were announced at the end of January 2020 7,8 reported relatively high efficacy, but a study conducted in South Africa showed a decrease in efficacy. This suggests that the effectiveness of existing vaccines using the original genomic sequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be low against the variant of concern (VOC) B.1.351 (Table 1) . By January 31, 2021, a total of 59 countries had begun vaccination, and by January end, Israel had the highest vaccination rate of 54.7 doses per 100 persons, and then the vaccination rates were 33.7, 13.9, 10.0, 9.4, 3.2, 2.8, and 2.3 doses per 100 persons in the United Arab Emirates, UK, Bahrain, US, Italy, Germany, and France, respectively. 15 The Israeli Health Maintenance Organization made a promising report that out of a population of 163,000 individuals, 10 days after the second vaccination, only 31 got infected by COVID-19. 16 In countries where vaccination is underway in early February 2021, a decrease in the number of confirmed cases per day is observed (Fig. 2) . However, the interpretation of the effect of the overall reduction of confirmed cases deserves attention. The Republic of Korea has selected healthcare workers related to COVID-19, residents of long-term care facilities for the elderly, and workers as priority groups for COVID-19 vaccination. This is an approach to prevent a collapse of the medical system and reduce mortality. Until January 2021, only 5% of the confirmed cases of COVID-19 in Korea were over 80 years old, but they account for 56.2% of the deaths (Fig. 3) 17 and COVID-19 outbreak in long-term care facilities has been severely fatal. 18 Until now, COVID-19 infection by medical staff during work has not been commonly found in Korea, 19 but it has been shown that even with low exposure risk, healthcare workers are under emotional stress. 20 Damage to medical staff due to self-isolation after exposure is also an important factor to consider. that high-risk healthcare workers and adult populations according to age-specific risk should be prioritized in the context of limited vaccine availability. 21 In the United States, healthcare workers and long-term care facility residents are the top priority. The same trend is being followed in the UK, Germany, France, Canada, Australia, Sweden, and Japan. Prioritization tailored to the characteristics of minorities and national health risk factors is unique to each country. Australia and Canada have prioritized vaccinations for indigenous communities, while Saudi Arabia has a serious health problem caused by obesity, so the priority is determined according to the body mass index. In other words, the priorities for vaccination are determined from the viewpoint of maintaining the medical system, protecting the elderly population, and minorities. Although there are detailed adjustments that reflect the characteristics of each country, they are the same in a large framework ( Table 2) . The Republic of Korea uses specialized vaccination centers and pre-designated private medical institutions to administer COVID-19 vaccination. In the United States, vaccinations are performed at hospitals, outpatient clinics, public health clinics, and mobile units, but Pfizer's vaccine may be precluded. There are three main vaccination centers in the UK: large venue vaccination center, hospital hub, and local vaccination service. Germany has a system similar to that of Korea ( Table 3 ). The reason for using both large vaccination centers and local medical institutions for each country is to build an infrastructure that is suitable for the characteristics of different types of vaccines and enables mass-vaccination within a short time. Most of the vaccination with Pfizer's mRNA vaccine, which is widely used, is being carried out at a pre-designated location. This is because the mRNA vaccine is difficult to store and transport. In particular, Pfizer's vaccine needs to be transported at a cryogenic temperature of −70°C, and thorough preparation is required from the packaging stage (Fig. 4) . The United States has created a special system to transport Pfizer and Modena vaccines, and private companies, such as FedEx and United Parcel Service are participating as logistics partners. Both companies are responsible for the logistics of half of the country (Fig. 5) . Canada, on the other hand, utilizes a state-led logistics system, where a multidisciplinary team, including the Canadian armed forces, are cooperating with private logistics companies to conduct transportation ( Certain topics must be prepared during the vaccination process. The issues below will be the most frequently asked questions before and after vaccination, and it is important to prepare answers based on scientific evidence. Anaphylaxis after vaccination has been reported for the Pfizer vaccine. According to a report from the centers for disease control and prevention in the United States, the onset of symptoms was 13 minutes. Symptoms occurring within 15 minutes were 71% of the total, and within 30 minutes were 86%. 49 The cause of anaphylaxis is presumed to be polyethylene glycol (PEG) and PEG derivatives, such as polysorbates. 50 However, in Korea, since it is not possible to test for allergens in advance an observation period after vaccination of about 30 minutes is required, and vaccination facilities must be prepared for anaphylaxis. Manufacturing factory: Kalamazoo, MI (Pfizer), Central Hub: Irving, Tx (Moderna) Logistic partners: FedEx, UPS • FedEx and UPS are each responsible for one half of the country • Both UPS and FedEx will use high-tech tracking devices to monitor packages carrying the vaccines • Pfizer has also installed its own tracking system on these boxes • Vaccine shipments will be getting special treatment, including priority access at the airport Australia 47 Logistic partners: DHL and Linfox • Support vaccination for all, including people in rural and remote areas • Required to track and report the temperature of the vaccines at all times • Logistics partners will be responsible for transport and management of vaccination supplies such as needles, syringes, and personal protective equipment Canada 48 An immunization NOC has been established as part of federal logistical coordination • Supported by a multidisciplinary team of experts, including the Canadian Armed Forces • FedEx Express Canada and Innomar Strategies will support the NOC with logistics and vaccines UPS = United Parcel Service, NOC = National Operations Centre. In addition, based on the US report, if about 60,000 people are inoculated with the first dose of Pfizer's vaccine in Korea, the probability that at least one anaphylaxis will occur is 48.3%. Given the impact of response to initial adverse events on the confidence of future vaccinations, health authorities should pay special attention. The second dose may be missed because of an unstable vaccine supply or personal reasons. The United States Advisory Committee on Immunization Practices allows the administration of a second dose within a four-day period (e.g., days [17] [18] [19] [20] [21] . If more than 21 days have passed since the first dose was received, the second dose can be administered as soon as possible and the vaccination series will not need to be restarted. 51 Symptoms, such as fever, chills, and muscle pain may appear briefly in approximately 10% after COVID-19 vaccination. If these symptoms appear within 48 hours after vaccination and disappear after a short period of time, this may be a symptom after vaccination. However, if an individual has respiratory symptoms (cough, shortness of breath, sore throat), it may be related to COVID-19 and may require a screening test for COVID-19. There are considerations for taking premedication to relieve symptoms after vaccination. However, there is no recommendation to date, and some studies suggest that the use of antipyretic analgesics prior to vaccination may alter the immune response. 52,53 Therefore, no special premedication is required. Several previous studies have suggested that natural immunity by COVID-19 may not last long. There is also evidence that reinfection is possible. 8,54 Therefore, vaccination is also necessary from the viewpoint of immunity boosting. There is also no evidence that vaccination schedules, doses, or platforms should be different from those of the general population. Phase 3 clinical trial results of multiple vaccines suggest that past COVID-19 infections do not affect the safety of the vaccine. Vaccination should be performed regardless of prior exposure to COVID-19. Testing for COVID-19 prior to vaccination is not recommended. 51 Due to the lack of evidence, to date, most countries do not recommend simultaneous vaccination with other non-COVID-19 vaccines such as influenza. The US recommends that other vaccines be administered at least 14 days after the COVID-19 vaccine. 51 Surveillance of the safety of the COVID-19 vaccine and transparent disclosure of results are the most important factors in gaining public confidence. In the Republic of Korea, during the 2020 seasonal influenza vaccination program, there was controversy over death after vaccination due to violation of cold chain regulations, excessive media attention, and fear of COVID-19. 55 Later, through autopsy, epidemiological investigation, and comparison of mortality with the previous seasons, it was found that there was no scientific causal relationship. However, mass media has a great influence on the public during the period of crisis of infectious diseases. 56 It is very important to establish a systematic surveillance protocol for safety as much as the effectiveness of vaccines. Major countries are operating vaccine safety monitoring systems, but are strengthening their organizations and systems specifically to respond to COVID-19. The United States has already established a surveillance system, such as V-safe, 57 and the baseline of adverse reactions is constantly being monitored and measured through the vaccine safety datalink. 58 The UK collects vaccine adverse events through the 'yellow card scheme' and has created a specialized internet-based reporting tool for COVID-19. Internet-based adverse event reporting tools are also actively being used in Israel and other countries. Canada and Australia are building adverse reaction monitoring systems using mobile phone apps and short message services ( Preparing for the COVID-19 Vaccination The Yellow Card Scheme The Medicines and Healthcare products Regulatory Agency The system collects and monitors information on safety concerns about medicines, medical devices and e-cigarettes. This includes all adverse events as well as concerns related to product quality or counterfeit products. System contains COVID-19 yellow card reporting page. Germany 61 • Routine pharmacovigilance Paul-Ehrlich-Institut responsible for monitoring the safety of vaccines and biomedicines. Routine pharmacovigilance is based on established realtime monitoring of possible side effects. Smartphone app (SafeVac 2.0) will prospectively track the frequency and severity of adverse effects. • SafeVac 2.0 Australia 62 , 63 Passive surveillance TGA TGA collects reports of suspected side effects from health professionals and consumers and analyses them to detect signals for possible safety issues. • AEFI (adverse events following immunisation) Some people who receive COVID-19 vaccines will be sent follow-up SMS messages with a survey to ask if they have experienced any potential side effects. Reporting an adverse event during or after COVID-19 vaccination Even if vaccination begins this month, the social impact of COVID-19 will continue for the time being. Of course, by the first half of the year, most of the healthcare workers and elderlies living in long-term care facilities will be vaccinated; therefore, the death toll will decrease rapidly and the sustainability of the medical system will be guaranteed. However, even if herd immunity is established in November 2021, SARS-CoV-2 will not disappear from our society. The outbreak of clusters will go on, and SARS-CoV-2 will continue attacking the weakest link in society. 68 Another factor that makes us impatient is the influx of worrisome variants. The VOC B.1.1.7, discovered in the UK, has been proven to have a faster propagation speed and is a dominant variant in Europe. 69 It was also confirmed that the VOC found in South Africa reduced the effectiveness of the vaccine. 8 Another VOC was also found in Brazil, 70 and although this mutation was found in different countries, mutations in the same region were observed through convergent evolution. In other words, the global epidemic and its response act as selective pressures, and there is also a possibility of the acceleration of viral mutation. Viral mutations will continue if the pandemic persists, and humanity must strive for vaccination and worldwide dissemination. In addition, the ability of the vaccine platform to respond to the VOC should be utilized to the fullest, and evidence for boosting doses should be quickly accumulated. 71 It is also necessary to make efforts to respond to the VOC of Korea itself. Korea already mandates the submission of diagnostic tests at the time of entry and polymerase chain reaction tests at the time of quarantine release for overseas travelers, and scientific evidence has already been accumulated. 72 However, in addition to blocking overseas inflows, efforts to monitor the mutation of SARS-CoV-2 in Korea should continue. After all, viral mutation is a probabilistic problem. Social distancing, epidemiological investigation, and diagnostic testing should be continued until the acquisition of herd immunity. In response to COVID-19, Korea is actively using nonpharmaceutical interventions, such as stepwise social distancing. 2, 73 In the first half of 2021, since vaccinations would not be available to the general population, social distancing should be followed until sufficient vaccination is achieved for the general population. However, social distancing entails enormous economic damage. In particular, at the end of the third wave, authorities and policymakers are facing opposition from small business owners and selfemployed people. Pandemics are accompanied by serious socio-economic damage as well as the burden of diseases itself. Furthermore, policies, such as social distancing, increase damage. In countries that enforce strong social distancing, such as a lock-down, financial support is provided for the affected sectors ( Table 6) . Korea also needs a proactive approach regarding this. As epidemiological data on COVID-19 have accumulated, evidence has suggested that COVID-19 is less severe in adolescents and infants, 83 and that its transmission in schools is not serious in Korea. 84 Therefore, we can carefully consider resuming in-person classes as part of social reopening. In addition, vaccine trials for pregnant women and adolescents under the age of 18 are already in progress in the US and UK. To achieve sufficient herd immunity and prepare for social reopening, we need to secure additional vaccine supply and prepare scientific evidence to increase the indication of vaccines for adolescents, pregnant 78 • Support rent fees for difficulty continuing business due to COVID-19 -Decreased by more than 50% compared to the same month of the previous year -Decreased by more than 30% compared to then same period of last year for consecutive 3 mon • Up to 6 months of then rental fee • Maximum 5 million yen for corporations -2.5 million yen for individual businesses Germany 79 Soforthilfe (emergency aid program) • Emergency aid program worth 50 billion euros • The temporary support will reimburse: -80 per cent of fixed costs, where turnover has dropped by more than 70 per cent -50 per cent where turnover has dropped by between 50 and 70 per cent -40 per cent where turnover has dropped by at least 40 and less than 50 per cent -The maximum support is 150,000 euros for three months. -For companies with up to 5 employees, the maximum sum that can be reimbursed is 9,000 euros for 3 mon. -For companies with up to 10 employees, the maximum sum that can be reimbursed is 15,000 euros for 3 mon. -In exceptional and justified cases -small businesses with extremely high fixed costs -support may be granted more than these ceilings. • No obligation to repay it in the future. Australia Coronavirus supplement 80 • Subsidy for equivalent to $550 per 2 wk ($275 per wk) -Self-employed persons whose business is closed because of a decrease in customers or whose income has decreased. Increasing the instant asset write-off 81 • From March 12, 2020 until December 31, 2020, the instant asset is written off: -Threshold is $150,000 (up from $30,000). -Eligibility range covers businesses with an aggregated turnover of less than $500 million (up from $50 million). JobMaker Hiring Credit 80 • The JobMaker Hiring Credit will be: -$200 per wk for each eligible employee aged 16 to 29 -$100 per wk for each eligible employee aged 30 to 35 Boosting cash flow for employers 80 • Providing up to $100,000 to eligible small and medium sized businesses and not-for-profits Taiwan 82 Subsidy program for the selfemployed • Receive NT$10,000 (EUR 330) for up to 3 mon -Taiwan citizenship -Enrolled in the labor insurance scheme through a professional union on or before March 31, 2020 -Salary in March 2020 was NT$24,000 (EUR 700) or less -Taxable income in 2018 was NT$408,000 (EUR 12,200) or less COVID-19 = coronavirus disease 2019, NT = New Taiwan dollar. women, and children in the second half of this year with the results of overseas clinical trials and approval status. 'Test and trace' was the driving force to prevent a large-scale outbreak in Korea despite the continuing community transmission. However, diagnostic tests and epidemiological investigations are carried out by human power, and it is essential to consider continuously exhausting human resources. In addition, cases of not actively participating in epidemiological investigations or interfering with epidemiological investigations are increasing. This means that prior to demanding active participation of citizens, legal and ethical considerations, such as personal information protection, should be sufficiently undertaken in the epidemiological investigation process. The COVID-19 pandemic still has a long way to run and just passed another turning point. The emergence of outbreak waves and VOCs during the hope of establishing herd immunity through vaccination is making the situation difficult. However, transparent communication and rational decision-making based on scientific evidence will be a beacon in overcoming this crisis. Covid 19: Christmas relaxation will overwhelm services Application of testing-tracing-treatment strategy in response to the COVID-19 outbreak in Seoul A perspective on multiple waves of influenza pandemics Korea Centers for Disease Control & Prevention. Free Vaccination for All Citizens of COVID-19 to Return to Daily Life. Cheongju: Korea Centers for Disease Control & Prevention Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Johnson announces single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its Phase 3 ENSEMBLE Trial Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera Moderna COVID-19 vaccine retains neutralizing activity against emerging variants first identified in the U.K. and the Republic of South Africa Oxford-AstraZeneca COVID-19 vaccine efficacy Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC Study shows Oxford Covid vaccine has less protection against South African variant Our World in Data. Coronavirus (COVID-19) vaccinations Vaccine found 92% effective in Israel, in first controlled result outside trials Improving preparedness for and response to coronavirus Disease 19 (COVID-19) in long-term care hospitals in Korea Risk of COVID-19 transmission from infected outpatients to healthcare workers in an outpatient clinic COVID-19 outbreak and its association with healthcare workers' emotional stress: a cross-sectional study World Health Organization. Who sage road map for prioritizing uses of COVID-19 vaccines in the context of limited supply The advisory committee on immunization practices' updated interim recommendation for allocation of COVID-19 Vaccine -United States Joint Committee on Vaccination and Immunisation. Advice on priority groups for COVID-19 vaccination Beschluss der STIKO zur 1. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung Preliminary advice on general principles to guide the prioritisation of target populations in a COVID-19 vaccination program in Australia Guidance on the prioritization of initial doses of COVID-19 vaccine(s) COVID-19 vaccines: what prioritization strategy at the start of the campaign? Nationell plan för vaccinationmot COVID-19 COVID-19: what's Sweden's priority list for the vaccine? Japan's COVID-19 vaccine plan prioritizes health care workers and older residents Outpacing Trump's operation warp speed, China to give coronavirus vaccine to 50 million in a month Everything you need to know COVID-19 VACCINE Ministry of Health. News. MOH announces priority groups for COVID-19 vaccination Division of Epidemiology. COVID-19 vaccine priorities COVID-19 vaccination information Fact sheet: explaining operation warp speed Department of Health & Social Care COVID-19 and vaccination: Answers to frequently asked questions (FAQ) Australia's COVID-19 vaccine national roll-out strategy COVID-19 immunization plan Ontario expands COVID-19 vaccine locations Ministère des solidarités, de la santé. The vaccine strategy High registration turnout to receive COVID-19 vaccine in Saudi Arabia The Minister of Health held tonight (Monday) a status assessment at the vaccine control center S. starts delivery of Moderna's COVID-19 vaccine Here's how the U.S. plans to deliver it Contracts signed for roll out of COVID-19 vaccine Canada's COVID-19 immunization plan: saving lives and livelihoods Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine-United States Allergic reactions to the first COVID-19 vaccine: a potential role of Polyethylene glycol? Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States The use of analgesics during vaccination with a live attenuated Yersinia pestis vaccine alters the resulting immune response in mice Effect of antipyretic analgesics on immune responses to vaccination What reinfections mean for COVID-19 Epidemiologic evaluation and risk communication regarding the recent reports of sudden death after influenza vaccination in the COVID-19 pandemic The relationships among media usage regarding COVID-19, knowledge about infection, and anxiety: Structural model analysis Vaccine safety Datalink (VSD) Ensuring the safety of COVID-19 vaccines in the United States Monitoring COVID-19 vaccine safety in national immunisation programmes Coronavirus and COVID-19 COVID-19 vaccine: information for consumers and health professionals Canadian Adverse Events Following Immunization Surveillance System (CAEFISS) French-news/Covid-19-vaccine-in-France-Side-effect-monitoring-increased-asvaccination-rolled-out se/en/reporting-adverse-reactions-events-and-incidents/suspected-adverse-reactionsfrom-medicinal-products/medicinal-products-for-humans/management-of-suspected-adverse-reactionreports Ministry of Health. COVID-19 vaccine FAQs Coronavirus disease 2019 outbreak at nightclubs and distribution centers after easing social distancing: vulnerable points of infection 1.1.7 in England: insights from linking epidemiological and genetic data Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the Spike protein COVID-19: Moderna plans booster doses to counter variants The importance of mandatory COVID-19 diagnostic testing prior to release from quarantine Stepwise strategy of social distancing in Korea Check if you can claim a grant through the self-employment income support scheme How do I apply for small business or self-employment benefits? Économie M. des Finances et de la Relance. Coronavirus COVID-19: Soutien aux entreprises Japan's ruling bloc agrees on rent relief plan for virus-hit firms The Federal Government. Temporary support for small and medium businesses Government response to coronavirus Instant asset write-off for eligible businesses ?g=83f1285d-94f4-4b0e-8e48-fe36bf7017aa. Updated 2020. Accessed Stepwise school opening and an impact on the epidemiology of COVID-19 in the children Children with COVID-19 after reopening of schools I am grateful to Professor Rugyeom Lee of Gachon University and Ms. Munkhzul Radnaabaatar, who helped collect and review the data in the article. In addition, I thank In Joong Kim, DVM, MS, PhD, DACVP and Tae Hyung Kim of Theragen Bio Co., Ltd. for providing the idea of the review.